168 related articles for article (PubMed ID: 34480380)
1. MPS I: Early diagnosis, bone disease and treatment, where are we now?
Kingma SDK; Jonckheere AI
J Inherit Metab Dis; 2021 Nov; 44(6):1289-1310. PubMed ID: 34480380
[TBL] [Abstract][Full Text] [Related]
2. Genotype-phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry.
Clarke LA; Giugliani R; Guffon N; Jones SA; Keenan HA; Munoz-Rojas MV; Okuyama T; Viskochil D; Whitley CB; Wijburg FA; Muenzer J
Clin Genet; 2019 Oct; 96(4):281-289. PubMed ID: 31194252
[TBL] [Abstract][Full Text] [Related]
3. Mucopolysaccharidosis type I.
Wraith JE; Jones S
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure.
de Ru MH; Boelens JJ; Das AM; Jones SA; van der Lee JH; Mahlaoui N; Mengel E; Offringa M; O'Meara A; Parini R; Rovelli A; Sykora KW; Valayannopoulos V; Vellodi A; Wynn RF; Wijburg FA
Orphanet J Rare Dis; 2011 Aug; 6():55. PubMed ID: 21831279
[TBL] [Abstract][Full Text] [Related]
5. Residual α-L-iduronidase activity in fibroblasts of mild to severe Mucopolysaccharidosis type I patients.
Oussoren E; Keulemans J; van Diggelen OP; Oemardien LF; Timmermans RG; van der Ploeg AT; Ruijter GJ
Mol Genet Metab; 2013 Aug; 109(4):377-81. PubMed ID: 23786846
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry.
D'Aco K; Underhill L; Rangachari L; Arn P; Cox GF; Giugliani R; Okuyama T; Wijburg F; Kaplan P
Eur J Pediatr; 2012 Jun; 171(6):911-9. PubMed ID: 22234477
[TBL] [Abstract][Full Text] [Related]
7. Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement.
Hampe CS; Wesley J; Lund TC; Orchard PJ; Polgreen LE; Eisengart JB; McLoon LK; Cureoglu S; Schachern P; McIvor RS
Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33572941
[TBL] [Abstract][Full Text] [Related]
8. Clinical manifestations and treatment of mucopolysaccharidosis type I patients in Latin America as compared with the rest of the world.
Muñoz-Rojas MV; Bay L; Sanchez L; van Kuijck M; Ospina S; Cabello JF; Martins AM
J Inherit Metab Dis; 2011 Oct; 34(5):1029-37. PubMed ID: 21541721
[TBL] [Abstract][Full Text] [Related]
9. Open issues in Mucopolysaccharidosis type I-Hurler.
Parini R; Deodato F; Di Rocco M; Lanino E; Locatelli F; Messina C; Rovelli A; Scarpa M
Orphanet J Rare Dis; 2017 Jun; 12(1):112. PubMed ID: 28619065
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy in mucopolysaccharidosis type I: progress and emerging difficulties.
Wraith JE
J Inherit Metab Dis; 2001 Apr; 24(2):245-50. PubMed ID: 11405343
[TBL] [Abstract][Full Text] [Related]
11. Early Neonatal Cardiac Phenotype in Hurler Syndrome: Case Report and Literature Review.
Pillai NR; Ahmed A; Vanyo T; Whitley CB
Genes (Basel); 2022 Jul; 13(8):. PubMed ID: 35893030
[TBL] [Abstract][Full Text] [Related]
12. Hurler-Scheie syndrome in Niger: a case series.
Assadeck H; Toudou Daouda M; Bako H; Hassane Djibo F
J Med Case Rep; 2019 Apr; 13(1):102. PubMed ID: 31018863
[TBL] [Abstract][Full Text] [Related]
13. Experiences of parents and patients with the timing of Mucopolysaccharidosis type I (MPS I) diagnoses and its relevance to the ethical debate on newborn screening.
de Ru MH; Bouwman MG; Wijburg FA; van Zwieten MC
Mol Genet Metab; 2012 Nov; 107(3):501-7. PubMed ID: 22926196
[TBL] [Abstract][Full Text] [Related]
14. Early enzyme replacement therapy enables a successful hematopoietic stem cell transplantation in mucopolysaccharidosis type IH: Divergent clinical outcomes in two Japanese siblings.
Yamazaki N; Kosuga M; Kida K; Takei G; Fukuhara Y; Matsumoto H; Senda M; Honda A; Ishiguro A; Koike T; Yabe H; Okuyama T
Brain Dev; 2019 Jun; 41(6):546-550. PubMed ID: 30755342
[TBL] [Abstract][Full Text] [Related]
15. Growth patterns for untreated individuals with MPS I: Report from the international MPS I registry.
Viskochil D; Clarke LA; Bay L; Keenan H; Muenzer J; Guffon N
Am J Med Genet A; 2019 Dec; 179(12):2425-2432. PubMed ID: 31639289
[TBL] [Abstract][Full Text] [Related]
16. IDUA mutational profile and genotype-phenotype relationships in UK patients with Mucopolysaccharidosis Type I.
Ghosh A; Mercer J; Mackinnon S; Yue WW; Church H; Beesley CE; Broomfield A; Jones SA; Tylee K
Hum Mutat; 2017 Nov; 38(11):1555-1568. PubMed ID: 28752568
[TBL] [Abstract][Full Text] [Related]
17. Early disease progression of Hurler syndrome.
Kiely BT; Kohler JL; Coletti HY; Poe MD; Escolar ML
Orphanet J Rare Dis; 2017 Feb; 12(1):32. PubMed ID: 28193245
[TBL] [Abstract][Full Text] [Related]
18. Capturing phenotypic heterogeneity in MPS I: results of an international consensus procedure.
de Ru MH; Teunissen QG; van der Lee JH; Beck M; Bodamer OA; Clarke LA; Hollak CE; Lin SP; Rojas MV; Pastores GM; Raiman JA; Scarpa M; Treacy EP; Tylki-Szymanska A; Wraith JE; Zeman J; Wijburg FA
Orphanet J Rare Dis; 2012 Apr; 7():22. PubMed ID: 22524701
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic cell transplantation for severe MPS I in the first six months of life: The heart of the matter.
Braunlin E; Miettunen K; Lund T; Luquette M; Orchard P
Mol Genet Metab; 2019 Feb; 126(2):117-120. PubMed ID: 30503158
[TBL] [Abstract][Full Text] [Related]
20. Laronidase treatment of mucopolysaccharidosis I.
Wraith EJ; Hopwood JJ; Fuller M; Meikle PJ; Brooks DA
BioDrugs; 2005; 19(1):1-7. PubMed ID: 15691212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
